RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
207 hedge funds and large institutions have $3.62B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 63 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
12% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 43
Holders
207
Holding in Top 10
9
Calls
$71.1M
Puts
$51.8M
Top Buyers
| 1 | +$112M | |
| 2 | +$43.5M | |
| 3 | +$22.6M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$20.9M |
Top Sellers
| 1 | -$80.6M | |
| 2 | -$24.5M | |
| 3 | -$24.5M | |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.6M |